Federated Hermes’s Fulcrum Therapeutics FULC Stock Holding History

Federated Hermes’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.8K	Buy	8,413 +8,085	+2,465%	+$49.2K	﹤0.01%	1748
2026 Q1	$2.52K	Hold	328	–	–	﹤0.01%	1954
2025 Q4	$3.71K	Hold	328	–	–	﹤0.01%	1919
2025 Q3	$3.02K	Buy	+328	New	+$2.37K	﹤0.01%	1994
2024 Q4	–	Sell	-25,401	Closed	-$90.7K	–	2118
2024 Q3	$90.7K	Buy	+25,401	New	+$188K	﹤0.01%	1578
2023 Q2	–	Sell	-1,385	Closed	-$3.95K	–	2150
2023 Q1	$3.95K	Buy	+1,385	New	+$12.4K	﹤0.01%	1954
2021 Q4	–	Sell	-71	Closed	-$2K	–	2237
2021 Q3	$2K	Sell	71 -587	-89%	-$11.1K	﹤0.01%	2094
2021 Q2	$7K	Buy	+658	New	+$6.65K	﹤0.01%	2008

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes's FULC Position: Q2 2026 in Review

Federated Hermes increased its Fulcrum Therapeutics (FULC) stake by 2,465% in Q2 2026, buying an estimated $49.2K and bringing the position to 8,413 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Federated Hermes first reported a position in FULC in Q2 2021 and has held it in 8 quarters since. The position peaked at $90.7K in Q3 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Federated Hermes held 8,413 shares of Fulcrum Therapeutics worth $30.8K as of Q2 2026.
Federated Hermes bought 8,085 Fulcrum Therapeutics shares in Q2 2026, an estimated $49.2K.
Fulcrum Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1748 holding.
Federated Hermes first reported a position in Fulcrum Therapeutics in Q2 2021 and has held it in 8 quarters since.
Federated Hermes's Fulcrum Therapeutics position peaked at $90.7K in Q3 2024.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.